The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis

PURPOSE: To systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-L1 antibodies for treatment of patients with advanced or refractory cancer. RESULTS: Fifty-one trials including 6,800 patients were included. The overall response rates for melanoma, non-small cell lung cance...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Zhang, Tengfei, Xie, Jing, Arai, Seiji, Wang, Liping, Shi, Xuezhong, Shi, Ni, Ma, Fen, Chen, Sen, Huang, Lan, Yang, Li, Ma, Wang, Zhang, Bin, Han, Weidong, Xia, Jianchuan, Chen, Hu, Zhang, Yi
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341964/
https://ncbi.nlm.nih.gov/pubmed/27683031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12230
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki